Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

PLYMOUTH MEETING, Pa., Aug. 11, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)."  The data demonstrate that a majority of patients experienced continued improvement, as measured by the number of surgical procedures needed after treatment with INO-3107, beyond the initial 12-month study period of the previously published Phase 1/2 trial. 

Read more at prnewswire.com